Chiesi Group is looking for groundbreaking solutions in Neonatal Respiratory Care.
Neonatal Respiratory Distress Syndrome (NRDS) and Bronchopulmonary Dysplasia (BPD) are critical challenges in neonatal care, impacting survival and long-term health.
Key NRDS Challenges:
- Limited access to neonatal care and surfactant therapy, especially in underserved areas.
- Lack of reliable early diagnostic tools beyond FiO₂.
- Need for less invasive treatments and reduction of comorbidities like BPD.
Key BPD Challenges:
- No standardised definition, leading to inconsistent diagnosis and treatment.
- Lack of targeted therapies to reduce severity and long-term impact.
Chiesi Group is looking for innovative and sustainable solutions to improve neonatal care, focusing on:
- Early diagnosis & risk assessment (biomarkers, predictive models) also of possible comorbidities.
- Non-invasive monitoring (NICU & home settings).
- Smart, sustainable drug delivery & neonatal care solutions.
- Digital health innovations (apps for baby monitoring).
- Expanded neonatal care access, especially in low-resource settings.
Examples of Potential Innovations: Predictive -OMIC profiling, genetic testing, parental risk profiling, regenerative stem cell therapies, smart NICU solutions, remote monitoring, mHealth support, and improved enteral nutrition.